


# Metergoline

**ALTERNATE NAMES:** Liserdol; benzyl N-[[[(6aR,9S,10aR)-4,7-dimethyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinolin-9-yl]methyl]carbamate; (((8-beta)-1,6-Dimethylergolin-8-yl)methyl)carbamic acid benzyl ester; (((8-beta)-1,6-Dimethylergolin-8-yl)methyl)carbamic acid phenylmethyl ester

**CATALOG #:** B3088-5 5 mg  
B3088-25 25 mg

**STRUCTURE:**



**MOLECULAR FORMULA:** C<sub>25</sub>H<sub>29</sub>N<sub>3</sub>O<sub>2</sub>

**MOLECULAR WEIGHT:** 403.5

**CAS NUMBER:** 17692-51-2

**APPEARANCE:** White to pale yellow powder

**PURITY:** ≥ 98%

**SOLUBILITY:** ~25 mg/ml in DMSO  
~5 mg/ml in ethanol  
~30 mg/ml in DMF

**DESCRIPTION:** Metergoline is a serotonin (5-HT) receptor antagonist. It is active at 5-HT1 (pK<sub>i</sub>=7.8 for 5-HT1B), 5-HT2 (pK<sub>i</sub>=8.64, 8.75 and 8.75 for 5-HT2A, 5-HT2B and 5-HT2C respectively) and 5-HT7 (pK<sub>i</sub>=16 nM) receptor subtypes. Metergoline potently inhibits 5-HT radiolabeling of the human 5-hydroxytryptamine(7) receptor, with an IC<sub>50</sub> value of 73 nM. It inhibits 5-HT7 receptor-stimulated cAMP production with an IC<sub>50</sub> of 321 nM in HEK293 cells.

**STORAGE TEMPERATURE:** -20°C. Protect from air. Store under desiccating conditions.

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**REFERENCES:**

1. Knight, J.A., Smith, C., Toohey, N., et al. Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine<sub>7</sub> receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists. *Mol. Pharmacol.* 75(2), 374-380 (2009).
2. Knight, A.R., Misra, A., Quirk, K., et al. Pharmacological characterisation of the agonist radioligand binding site of 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> receptors. *Naunyn Schmiedebergs Arch. Pharmacol.* 370(2), 114-123 (2004).
3. Millan, M.J., Newman-Tancredi, A., Lochon, S., et al. Specific labelling of serotonin 5-HT<sub>1B</sub> receptors in rat frontal cortex with the novel, phenylpiperazine derivative, [<sup>3</sup>H]GR125,743. A pharmacological characterization. *Pharmacol. Biochem. Behav.* 71(4), 589-598 (2002).

**RELATED PRODUCTS:**

Pimavanserin Tartrate (Cat. No. B1915)  
 Vortioxetine Hydrobromide (Cat. No. B3232)  
 Chlorpromazine Hydrochloride (Cat. No. B1992)  
 Eltoprazine hydrochloride (Cat. No. B2301)  
 Sertraline (hydrochloride) (Cat. No. B2393)

**DISCLAIMER:** **FOR RESEARCH USE ONLY! Not to be used on humans.**